Stockreport

Imara Reports Full Year 2020 Financial Results and Business Highlights

IMARA Inc.  (IMRA) 
PDF Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a [Read more]